Your session is about to expire
← Back to Search
Monoclonal Antibodies
LIB003 (lerodalcibep) Process 1 for High Cholesterol
Phase 3
Waitlist Available
Led By Traci A Turner, MD
Research Sponsored by LIB Therapeutics LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights
Summary
This trial is testing a new drug called LIB003, given as an injection under the skin. It aims to see how well it works in people who are either taking statins or not. The drug is expected to lower bad cholesterol levels in the blood.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
AUC 0-last pharmacokinetics
Cmax pharmacokinetics
T-Half pharmacokinetics
+1 moreSecondary study objectives
comparison of LDL-C
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: LIB003 (lerodalcibep) Process 1Experimental Treatment1 Intervention
300 mg LIB003 Process 1 drug product administered SC
Group II: LIB003 (lerodalcibep) Process 2Active Control1 Intervention
300 mg LIB003 Process 2 drug product administered SC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
lerodalcibep
2022
Completed Phase 3
~770
Find a Location
Who is running the clinical trial?
Medpace, Inc.Industry Sponsor
96 Previous Clinical Trials
29,849 Total Patients Enrolled
LIB Therapeutics LLCLead Sponsor
10 Previous Clinical Trials
4,883 Total Patients Enrolled
Traci A Turner, MDPrincipal InvestigatorMetabolic & Atherosclerosis Research Center
1 Previous Clinical Trials
63 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger